Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) has been suspected of causing de novo copy number variation [1] [2] [3] [4] . To explore this issue, here we perform a whole-genome and transcriptome analysis of 20 human iPSC lines derived from the primary skin fibroblasts of seven individuals using next-generation sequencing. We find that, on average, an iPSC line manifests two copy number variants (CNVs) not apparent in the fibroblasts from which the iPSC was derived. Using PCR and digital droplet PCR, we show that at least 50% of those CNVs are present as low-frequency somatic genomic variants in parental fibroblasts (that is, the fibroblasts from which each corresponding human iPSC line is derived), and are manifested in iPSC lines owing to their clonal origin. Hence, reprogramming does not necessarily lead to de novo CNVs in iPSCs, because most of the line-manifested CNVs reflect somatic mosaicism in the human skin. Moreover, our findings demonstrate that clonal expansion, and iPSC lines in particular, can be used as a discovery tool to reliably detect low-frequency CNVs in the tissue of origin. Overall, we estimate that approximately 30% of the fibroblast cells have somatic CNVs in their genomes, suggesting widespread somatic mosaicism in the human body. Our study paves the way to understanding the fundamental question of the extent to which cells of the human body normally acquire structural alterations in their DNA post-zygotically.
The ability to derive iPSCs from somatic cells [5] [6] [7] [8] has opened exciting new possibilities for the study of human development and regenerative medicine, and has enabled the effect of human genetic variation on developmental processes to be examined [9] [10] [11] [12] [13] . However, all of these applications require that iPSCs, clonal cell lines each derived from one or just a few somatic cells, stably maintain the genetic background of the individual from whom they are derived. Yet, there are reports of genomic instability in stem and precursor cells, indicating that copy number variation/structural variation might arise in iPSCs, in addition to single base-pair changes [1] [2] [3] [4] [14] [15] [16] . These variations could be caused by the de-differentiation procedures, result from extensive time in culture, or pre-exist in the somatic tissue of origin at low frequency. Emerging evidence suggests potentially widespread genomic mosaicism not only in cancer but also in somatic cell lineages, as a result of errors during DNA replication, DNA repair, mitosis and mobilization of transposable elements [17] [18] [19] [20] [21] . Such a phenomenon could have farreaching physiological consequences yet is still poorly understood and very difficult to study [22] [23] [24] [25] . The derivation of iPSCs offers the opportunity to analyse the genome of a single cell at high resolution and sensitivity.
Using the canonical retroviral method, we have produced 21 human iPSC (hiPSC) lines derived from skin fibroblasts collected from seven members of two families ( Supplementary Fig. 1 ). The hiPSC lines were characterized by four sets of quality control criteria: (1) morphology;
(2) expression of pluripotency factors at the protein level; (3) gene expression analyses (reverse transcription PCR (RT-PCR), microarrays, complete transcriptome by high-throughput RNA sequencing (RNA-seq)); and (4) demethylation of canonical pluripotency factor promoters (Supplementary Figs 2 and 3 and Supplementary Tables  1 and 2 ). This thorough evaluation (Supplementary Information) showed there was extensive similarity between our hiPSCs and human embryonic stem cells, and divergence of hiPSCs from the fibroblasts, indicating complete reprogramming. Finally, by using neuronal differentiation assays, we found that the hiPSCs exhibited comparable propensities for neural lineage differentiation ( Supplementary Fig. 4) .
We then generated one lane of whole-genome paired-end sequencing data on the Illumina HiSeq platform for 20 hiPSC lines, and predicted CNVs in hiPSC lines with CNVnator 26 ( Supplementary  Fig. 1b ). CNVnator uses read-depth analysis and was shown to have the highest sensitivity in confirming CNVs previously discovered with arrays and fosmid sequencing 27 . First, we discovered CNVs in fibroblast and hiPSC samples by comparison with the reference human genome, and then compared genotypes of each hiPSC line to their respective fibroblast cell population of origin to identify the variants manifested only in hiPSCs, that is, line-manifested CNVs (LM-CNVs). We were able to discover CNVs as small as 2 kilobases (kb), but the highest sensitivity was for CNVs of at least 5 kb in size ( Supplementary  Fig. 5 ). Using conservative criteria, we predicted a total of 74 LM-CNVs in all 20 lines ( Supplementary Table 3 ), that is, just a few LM-CNVs per line. Similar numbers of LM-CNVs per line were observed for a few other hiPSC lines produced by the episomal method (Supplementary Information).
We observed positive yet non-significant correlations between the number of LM-CNVs and the passage number at which hiPSC lines were sequenced ( Fig. 1a ). Neither more relaxed CNV calling nor more sensitive criteria for LM-CNV identification made the correlation significant. LM-CNVs represent a small fraction of all CNVs that were discovered in hiPSC lines by comparison with the reference human genome and performing read-depth analysis at higher coverage (,203) did not change the proportion of LM-CNVs versus the total number of CNVs ( Fig. 1b ). Even with sensitive criteria for LM-CNV prediction, their fraction did not exceed 17%. As a positive control and using the same approach, we compared an hiPSC line to the fibroblasts of an individual from the other family and observed roughly 40 different CNVs per comparison (that is, significantly more than the number of LM-CNVs per hiPSC line, Fig. 1c ), which is consistent with interindividual variations in a similar size range, as described previously 27 .
Discordant paired-end reads analysis confirmed 22 LM-CNVs discovered by read-depth analysis (Supplementary information). For 39 of the most confident predictions, we performed quantitative PCR (qPCR) validation assays in early passage hiPSCs (passages 5-13), and also, when available, in late passage cells (passages 17-52) (see below). These analyses validated 33 LM-CNVs (Table 1 , Supplementary Table 3 and Supplementary Figs 6-44 ). Validated LM-CNVs were present in 15 out of 20 (75%) hiPSC lines, with 9 (45%) hiPSC lines having more than one LM-CNV.
To obtain an independent confirmation of our approach for LM-CNV detection, we analysed the hiPSC and fibroblast samples from the mother of family S1123 and the proband of family 03 by high-resolution array-based comparative genome hybridization (aCGH). All of the 10 LM-CNVs validated by qPCR (Table 1) , which were found by sequencing in the hiPSCs from these individuals, were also confirmed by aCGH ( Supplementary Figs 45-54 ). However, no further LM-CNVs could be discovered using aCGH data, as the estimated false discovery rate (FDR) of the set of other predictions was close to 100%, based on qPCR validation of a random subset ( Supplementary Tables 4 and 5 ). These data suggest that analysis of sequencing data alone allows the discovery of all or almost all LM-CNVs. Finally, we tested by qPCR the presence of validated LM-CNVs at later passages (passages 17-52), in five hiPSC lines. We observed a strong correlation (Pearson's coefficient 0.96) between qPCR results obtained in late versus early passages ( Supplementary Fig. 6 ). Among 16 LM-CNVs that were tested, 87.5% were validated in late passage (Table 1 ), suggesting long-term stability of the hiPSC genome.
We then analysed the origin of LM-CNVs, that is, whether they had arisen de novo in the hiPSCs as a sequel to reprogramming or were present at low allele frequencies in the donor fibroblast population. The first indirect, but suggestive evidence for fibroblast somatic genomic heterogeneity was the observation of the same validated LM-CNVs (chrX:64962001-65029000) in two different hiPSC lines (3 and 4) derived from the fibroblast culture of the same individual ( Table 1 , Fig. 2a and Supplementary Fig. 55 ). Further evidence for genomic heterogeneity was the realization that for many CNVs, copy number ratios were deviating from 1.5, indicative of one haplotype duplication, or from 0.5, indicative of one haplotype deletion, using both read-depth analysis and their qPCR validation (Supplementary Fig. 6 and Supplementary Information).
To test for the actual presence of somatic CNVs in the fibroblast cultures, we performed PCR amplification with diagnostic primers across CNV breakpoints in hiPSCs and the corresponding donor fibroblasts for 20 LM-CNVs with good initial estimate of their breakpoints from paired-end analyses ( Fig. 2b , Table 1 and Supplementary  Table 3 ). We observed expected bands in all cases when using hiPSC DNA, and in eight cases when using DNA from the corresponding fibroblast cultures (Supplementary Table 3 ; see Fig. 2b , e, g for representative examples and Supplementary Figs 7-39 ). For 15 LM-CNVs we also performed digital droplet PCR (ddPCR) ( Fig. 2c ), which allows not only the observation of low-frequency somatic CNVs but also an estimation of their allelic frequency in the somatic mosaic, with a sensitivity down to 0.1%. From the allele frequencies, cellular frequencies in the fibroblasts were calculated as explained in the Methods using the LETTER RESEARCH ratio between the target and the control regions. The frequency of the duplication in chromosome X in fibroblast cells was estimated to be 12.6% (Fig. 2d ). Cell frequencies varied from 14.6% ( Fig. 2f ) to less than 1% ( Fig. 2h ) and are summarized in Table 1 (last column). In total, the use of PCR and ddPCR allowed us to establish the presence in the parental fibroblast culture of 10 out of 20 LM-CNVs (Table 1 ), suggesting that fibroblast somatic genomic heterogeneity can explain at least 50% of the LM-CNVs in hiPSCs (Supplementary Table 6 ).
Sanger capillary sequencing of PCR bands allowed us to determine breakpoints with base-pair resolution for 18 non-redundant LM-CNVs (Supplementary Data). Analysis of sequences around breakpoints suggests non-homologous end joining as a key mechanism in the creation of LM-CNVs. Finally, we examined whether LM-CNVs affect the expression of intersected genes. Statistical analysis, using Fischer's exact test, showed that with a P value of 0.01 there was a direct association of gene expression with its copy number, that is, duplications increased expression whereas deletions decreased it ( Supplementary Fig. 56 ).
In summary, we report genomic stability of hiPSC lines and the presence of extensive somatic mosaicism for copy number variation in the genome of human skin fibroblasts. This is the result of a systematic discovery and analysis of CNVs in 20 hiPSC lines relative to 7 fibroblast cultures from which the hiPSC lines were derived. As hiPSCs are clonally derived from just one or a few fibroblast cells, analysis of their genome allowed us to discover CNVs present in a subset of parental fibroblast cells, such that very low allele frequency variants in the original populations could be unmasked. We then used PCR and ddPCR across breakpoints to genotype CNVs in the parental fibroblasts, and estimated that 50% of the CNVs manifested in hiPSCs could be traced back to the original fibroblast population ( Table 1 ). We may be underestimating this phenomenon because very low allele frequency somatic CNVs might still escape confirmation by PCR/ddPCR in fibroblasts owing to technical limitations. Despite this, conceptually, our approach can be used for comparison of any clonal (not only iPSC) and parental cell populations with the aim of studying somatic variation.
Overall, we found that hiPSCs manifest on average two validated CNVs larger than 10 kb, which is considerably more than in two previous studies 1, 28 . The difference is probably attributable to us using sequencing (generally a more sensitive approach, see Supplementary Discussion) as opposed to single nucleotide polymorphism arrays 1 . One of the aforementioned studies 28 also used sequencing but analysed only three hiPSC lines, therefore by extrapolating to a larger number their results could still be consistent with ours. Alternatively, bone marrow mononuclear cells may have fewer somatic variations than fibroblast cells, explaining why hiPSC lines derived from mononuclear cells in the previous study 28 manifest fewer LM-CNVs than do our hiPSC lines derived from fibroblasts.
It was previously proposed that CNVs might arise in hiPSCs as a consequence of DNA damage or impaired DNA repair during reprogramming. Although we acknowledge that some CNVs might arise 
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during reprogramming in some hiPSC lines, our data suggest that reprogramming per se does not obligatorily induce de novo mutations, as at least half of the LM-CNVs preexisted in parental fibroblast cells ( Table 1) . We also found no significant difference in the number of LM-CNVs in relation to passage number. Thus, our analyses support neither the hypothesis 3 that hiPSCs generally have a large rate of de novo mutations nor the observation that most LM-CNVs in hiPSCs disappear in late passages 3 . Using different parental cells and applying different protocols for cell culturing could be the factors accounting for the difference in the results.
In six hiPSC lines we determined that at least one LM-CNV originated in parental fibroblast cells. Assuming that each hiPSC colony represents a single, clonally expanded cell, we estimate that 30% (6 out of 20) of skin fibroblast cells carry large somatic CNVs. To our knowledge, this is the first such estimate. Furthermore, with ddPCR, we estimated cell frequency as high as 15% and as low as a fraction of a per cent, suggesting wide variability in the extent of fibroblast mosaicism. Although it is possible that some CNVs could have arisen during the fibroblast cell culture 29 , we think this is unlikely given that they were passaged less than five times (and in most cases only three times) before proceeding with hiPSC generation.
It has been known for a while 22 that somatic variants can be responsible for various diseases, including cancer, and here we have provided evidence that the extent of somatic variation could have been markedly underestimated. If true, this needs to be taken into account when designing an hiPSC-based study. But more importantly, this finding LETTER RESEARCH may challenge widely adopted experimental designs for genetic analyses of diseases with complex inheritance in which only the genomes of lymphoblastoid cells are being analysed. By influencing the phenotype in unexpected ways, somatically acquired CNVs might represent at least part of the explanation for the challenges in identifying the genetic contribution in some of the complex and especially in neurodevelopmental diseases, for which determining the exact loci for genetic predisposition has proven difficult 30 .
METHODS SUMMARY
hiPSC lines were generated with Yamanaka's four retroviral vectors. One hundred nanograms of total RNA extracted from hiPSC lines was reverse-transcribed using SuperScript III Reverse Transcriptase and random hexamers. Primers used for OCT4 (also known as POU5F1), MYC (also known as c-Myc) and SOX2 specifically detect the transcripts from the endogenous genes. 
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METHODS iPSC generation. A skin biopsy was obtained from the inner area of the upper arm from each member of the two families using standard techniques. Informed consent was obtained from each subject enrolled in the study according to the regulations of the Institutional Review Board and Yale Center for Clinical Investigation at Yale University. Primary cultures of fibroblasts were derived using standard procedures and infected at passage 3 with Yamanaka's four retroviral vectors, encoding for the canonical reprogramming factors (OCT4 (also known POU5F1), SOX2, KLF4 and MYC) using a multiplicity of infection (m.o.i.) of 5. After 1 month in culture, colonies with the typical human embryonic stem-cell morphology were picked, expanded on Matrigel substrate in DMEM/F12 containing 1% N2 supplement, 2% B27 supplement, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1% penicillin/streptomycin, 0.5 mg ml 21 BSA fraction V (all from Invitrogen), 0.12 mM monothioglycerol (Sigma), and supplemented with 80 ng ml 21 recombinant human basic fibroblast growth factor (Millipore). Colonies were characterized by immunofluorescence, RT-PCR and gene expression (see below). RT-PCR. Total RNA was purified from hiPSC clones at passages between 5 and 13 using PicoPure RNA isolation kit (Arcturus). One hundred nanograms of total RNA extracted from hiPSC lines was reverse-transcribed using SuperScript III Reverse Transcriptase and random hexamers. Primers for embryonic stem-cell marker genes are described elsewhere 31 . Primers used for OCT4 (also known as POU5F1), MYC and SOX2 specifically detect the transcripts from endogenous genes. Neuronal differentiation. Neuronal differentiation was done by slightly modifying a protocol already used in the hiPSC field 13, 34 . Undifferentiated hiPSC colonies maintained on Matrigel were pre-incubated with the ROCK inhibitor (Y-27632), dissociated to single cells and then re-aggregated using V-bottom Aggrewell plates in serum-free medium containing recombinant noggin (200 ng ml 21 ). After 2 days, the resulting embryoid bodies were transferred to a Petri dish, cultured in suspension for a further 2 days, and then transferred to a Matrigel substrate in serum-free medium supplemented with noggin (200 ng ml 21 ), FGF2 (20 ng ml 21 ) and DKK1 (200 ng ml 21 ). After 24 h the embryoid bodies generated neuro-epithelial structures known as rosettes. A monolayer of neural progenitor cells was obtained after manual dissection, dissociation and replating of the neural rosettes on polyornithine-and laminin-coated dishes in the presence of FGF2 and EGF (both at 10 ng ml 21 ) that allowed for the expansion (three or four passages) of the proliferating neural progenitors. Microarrays for gene expression analysis. Total RNA isolated as above was analysed by HumanHT-12 v4 BEADCHIP Illumina microarrays. Values were analysed by GenomeStudio using quantile normalization and background subtraction. Differential scores were compared to values obtained from the federally approved H1 human embryonic stem-cell line. Library preparations for RNA and DNA sequencing. For RNA-seq libraries, polyadenylated RNA fragments were purified by a Dynabeads mRNA Purification kit (Invitrogen), fragmented (RNA fragmentation buffer, Ambion), and reverse transcribed into first-strand complementary DNA using random hexamer and superscript II (Invitrogen), followed by second-strand cDNA synthesis using RNaseH and DNA polymerase I (Invitrogen). The cDNA was end-repaired and added a single 'A' at the 39 ends before ligating with Illumina adaptors. After running on a gel, DNA fragments from 250 to 350 bp were cut out and extracted using MinElute gel purification kit (Qiagen), and PCR-amplified using Phusion High-Fidelity master mix and Illumina primers with the condition of 98 uC for 30 s, 15 cycles of 98 uC for 10 s, 65 uC for 30 s, and 72 uC for 30 s, and concluding with 72 uC for 5 min.
To make DNA libraries, the Illumina protocol of paired-end DNA sample preparation was followed with minor modification. In short, genomic DNA was sonicated to generate fragments ranging from 200 to 800 bp, which were endrepaired, 'A' attached at the end, ligated with Illumina paired-end adaptors, size selected (450-550 bp) on 2% E-gel (Invitrogen) and extracted from the gel. The final PCR step is the same as in RNA-seq library preparation but with 18 cycles. Conservative prediction of LM-CNVs in hiPSC. Using Burrows-Wheeler aligner (BWA) 0.5.9-r16 (ref. 35 ) aligner with options '-t 4 -q 15' we have aligned genomic sequence reads to the human reference genome used by the 1000 Genomes Project (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/technical/reference), which is based on hGRC37 and included unplaced contigs. Aligned reads were paired, mapped and sorted by BWA invoked with the following options '-a 1000 -n 1 -N 1'. As a result, for each sequenced sample we obtained a file with mapped reads in BAM format. To predict CNVs, the BAM files were processed by the CNVnator method 26, 36 , which is based on read-depth analysis (see ref. 27 for review). For analysis of genomes sequenced at low coverage we used 1,000-bp bins. For analysis of two genomes sequenced at high coverage we used 400-bp bins. Then, in hiPSCs and corresponding fibroblasts, we estimated/genotyped and compared (by CNVnator) the copy number of CNVs predicted in hiPSCs. In a normal cell, the copy number should be a whole number (for example, 0, 1 or 2); however, if the population of cells used for analysis is not heterogeneous, then the copy number can be a non-negative real number (for example, 1.5). We declared copy number variation as a line-manifested deletion candidate in hiPSCs compared to fibroblasts if (1) CN i , 1.5 and CN f . 1.5 and CN f -CN i . 0.5; or (2) CN i , 0.5 and CN f . 0.5 and CN f 2 CN i . 0.5 for X and Y chromosomes in samples collected from males, in which CN i and CN f denote copy number in iPSC and fibroblast samples, respectively. Similarly, we declared copy number variation as a line-manifested duplication candidate if (3) CN i . 2.5 and CN f , 2.5 and CN i 2 CN f . 0.5; or (4) CN i . 1.5 and CN f , 1.5 and CN i 2 CN f . 0.5 for X and Y chromosomes in samples collected from males. In other words, we considered copy number variation with an estimated allele frequency in fibroblasts of at least 25% and difference in allele frequency when compared to hiPSC lines of at least 25%. We then manually inspected the read-depth signal track to select the most confident LM-CNV candidates for validation. To select confident candidates, we relied on human expertise to evaluate visually the read-depth signal in the candidate regions, presence of discordant paired-end reads supporting a prediction (see below), as well as requiring very pronounced signals in regions of segmental duplications; we also took into account whether CNVs were previously discovered CNVs 27, 37 . Two copy number variation boundaries were re-estimated. Selected confident LM-CNV candidates have been validated experimentally by qPCR, aCGH, PCR and ddPCR. Sensitive prediction of LM-CNVs in hiPSCs. To perform a more sensitive CNV calling with CNVnator, we used option '-relax', which allowed us to find CNVs with allele frequencies down to 12.5% as opposed to 25% with the default options. Of note, the heterozygous deletion/duplications on a diploid chromosome have a 50% allele frequency. Furthermore, we relaxed the criteria on declaring a CNV as a LM-CNV. Specifically, we used the following criteria: (1) CN i , 1.7 and CN f . In other words, we considered CNVs with an estimated allele frequency in fibroblasts (down to 15%) and a difference in allele frequency (down to 15%) when compared to hiPSC lines. Obtaining further support for CNVs by paired-end analysis. To obtain further support for a predicted CNV, we searched for abnormally mapped paired-ends in hiPSC lines for which CNVs were predicted and in parental fibroblasts 38 . For a deletion, the supporting paired-ends must map with expected orientation but should have a larger span compared to the expected one from the sequencing library preparation. For a tandem duplication, the supporting paired-ends must map with an orientation different from the expected and also have a larger span ( Supplementary Fig. 57 ). Predicted duplications may be tandem or dispersed. For dispersed duplication we searched for clusters of paired-ends with one end mapping close to predicted duplication boundaries and the other ends clustering somewhere in genome. It is well known that CNVs are enriched for repeats and homologous sequences around breakpoints, where read mapping is ambiguous 39 . Thus, the absence of paired-end support for a predicted CNV does not invalidate the CNV. We considered a paired-end to support a deletion/duplication if it has a proper (for the type of CNV) pattern of read mapping, and its span and predicted CNV size has at least 80% mutual overlap. This condition and kilobase size of predicted CNVs guarantees that the span of supportive paired-ends is at least a few kilobases, which is much larger than the span expected from the sequencing library preparation, that is, 300-800 bp. Finally, although we did not require any particular read mapping quality, it was no less than 25 (meaning less than a 0.003 chance of incorrect mapping according to the mapper) for each supportive read. As only around 100 supportive reads were found, we do not expect any single one of them to be mapped incorrectly. qPCR for LM-CNV call validation. Primer pairs were designed using ProbeFinder software from Roche Applied Science (https://www.roche-appliedscience.com/sis/rtpcr/upl/index.jsp). From 2 to 4 kb of DNA near the centre of the presumed CNV was scanned by ProbeFinder and the primer pair design was confirmed by UCSC In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr) and LETTER RESEARCH
